SCHEMBL2360090

SCHEMBL2360090

COc1ccc(N2CCN(c3ccccc3)S2(=O)=O)nc1N1CCN(C)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.43
CYP3A4 P08684 4/20 0.43
TSHR P16473 2/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
HRH4 Q9H3N8 1/20 0.42
MAPT P10636 1/20 0.42
RAD52 P43351 1/20 0.42
HTR1A P08908 1/20 0.41
HTR1D P28221 1/20 0.41
HTR1B P28222 1/20 0.41
DRD2 P14416 1/20 0.41
DRD3 P35462 1/20 0.41
HTR6 P50406 3/20 0.41
CYP2D6 P10635 3/20 0.40
CYP2C19 P33261 2/20 0.40
USP2 O75604 2/20 0.40
ALOX15 P16050 1/20 0.40
HSD17B10 Q99714 1/20 0.40
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12445260 0.90 MAPT (0.45) CYP1A2HRH4MAPTHTR1AHTR1D
SCHEMBL2360158 0.89 HRH4 (0.44) HRH4MAPTHTR1AHTR1DHTR1B
SCHEMBL14733343 0.84 KMT2A (0.44) CYP1A2CYP3A4TSHRKMT2AHRH4
SCHEMBL2328041 0.81 HTR2A (0.44) CYP1A2CYP3A4TSHRMEN1KMT2A
SCHEMBL14733346 0.78 HRH4 (0.42) CYP1A2TSHRHRH4MAPTRAD52
SCHEMBL12444826 0.75 TSHR (0.39) TSHRKMT2AHRH4MAPTMAT2A
SCHEMBL14733345 0.73 HRH4 (0.42) MEN1KMT2AHRH4MAPTHTR1A
SCHEMBL2360469 0.71 HRH4 (0.45) CYP1A2MEN1KMT2AHRH4MAPT
SCHEMBL2333076 0.70 HRH4 (0.42) MEN1KMT2AHRH4MAPTHTR1A
SCHEMBL2359748 0.67 HRH4 (0.43) CYP1A2KMT2AHRH4MAPTHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130053372-A1 5-HT RECEPTOR MODULATORS CAMBRIDGE ENTERPRISE LIMITED 2013-02-28 US claimed
EP-2536711-A1 5-HT RECEPTOR MODULATORS Cambridge Enterprise Limited (GB) 2012-12-26 EP claimed
WO-2011098776-A1 5-HT RECEPTOR MODULATORS CAMBRIDGE ENTERPRISE LIMITED (GB) 2011-08-18 WO claimed
US-20130053372-A1 5-HT RECEPTOR MODULATORS CAMBRIDGE ENTERPRISE LIMITED 2013-02-28 US disclosed
US-20130053372-A1 5-HT RECEPTOR MODULATORS CAMBRIDGE ENTERPRISE LIMITED 2013-02-28 US disclosed
EP-2536711-A1 5-HT RECEPTOR MODULATORS Cambridge Enterprise Limited (GB) 2012-12-26 EP disclosed
WO-2011098776-A1 5-HT RECEPTOR MODULATORS CAMBRIDGE ENTERPRISE LIMITED (GB) 2011-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053372-A1 5-HT RECEPTOR MODULATORS HTR1B, HTR5A, HTR1A CYP1A2 627/4885CYP3A4 1601/4885TSHR 279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.